A Simple Model for Predicting Two-Year Risk of Diabetes Development in Individuals with Prediabetes
- PMID: 29309270
- PMCID: PMC5760055
- DOI: 10.7812/TPP/17-050
A Simple Model for Predicting Two-Year Risk of Diabetes Development in Individuals with Prediabetes
Abstract
Context: Given the dramatic rise in the incidence of type 2 diabetes mellitus (T2DM) in recent decades, identifying individuals at increased risk of T2DM and validating methods to reduce their risk of disease progression is important. With more than one-third of US adults having prediabetes, a more precise stratification of absolute risk of T2DM incidence would help in prioritizing prevention efforts.
Objective: To develop a simple and clinically useful schema to stratify short-term (2-year) absolute risk of T2DM.
Design: Observational study of more than 77,000 adult members (age 18-75 years) from 3 Regions of the Kaiser Foundation Health Plan with prediabetes (hemoglobin A1C [HbA1C] = 5.7%-6.4%).
Main outcome measures: The 2-year probability for development of diabetes as a function of baseline HbA1C and body mass index (BMI).
Results: The 2-year risk of diabetes diagnosis varied widely by HbA1C and BMI. A small subset (5.2%) had a very high risk of T2DM developing within 2 years. Another 13.3% had a moderate 2-year risk of T2DM, whereas most (81.5%) of the population was at much lower risk. Thus, most Kaiser Foundation Health Plan members with prediabetes have only modest risk of progression to T2DM within 2 years.
Conclusion: Using HbA1C and BMI, we created a simple stratification scheme to more precisely estimate risk of T2DM incidence. This will enable more efficient assignment of prevention interventions and clinical and laboratory follow-up to the small subset at highest risk, while minimizing the potentially negative effects of overdiagnosis among the majority with prediabetes who are not at high short-term risk of T2DM.
Conflict of interest statement
Dr Nichols receives unrelated research funding from Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany; Sanofi SA, Paris, France; Janssen Pharmaceuticals Inc, Titusville, NJ; and Amarin Pharma Inc, Bedminster, NJ. The author(s) have no other conflicts of interest to disclose.
Figures
References
-
- NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016 Apr 9;387(10027):1513–30. DOI: https://doi.org/10.1016/s0140-6736(16)00618-8. - DOI - PMC - PubMed
-
- Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: Dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010 Oct 22;8:29. DOI: https://doi.org/10.1186/1478-7954-8-29. - DOI - PMC - PubMed
-
- Diagnosed diabetes [Internet] Atlanta, GA: Centers for Disease Control and Prevention (CDC); 2015. [cited 2017 Oct 3]. Available from: https://gis.cdc.gov/grasp/diabetes/DiabetesAtlas.html.
-
- Centers for Disease Control and Prevention (CDC) National Diabetes Statistics Report, 2014: Estimates of diabetes and its burden in the United States [Internet] Atlanta, GA: US Department of Health and Human Services; 2014. [cited 2017 Sep 1]. Available from: https://stacks.cdc.gov/view/cdc/23442.
-
- American Diabetes Association. (2) Classification and diagnosis of diabetes. Diabetes Care. 2015 Jan;38 Suppl:S8–S16. DOI: https://doi.org/10.2337/dc15-S005. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
